A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.

doi:10.1038/s41467-020-20228-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.

Nature communications - 16 Dec 2020

Yahalom-Ronen Yfat, Tamir Hadas, Melamed Sharon, Politi Boaz, Shifman Ohad, Achdout Hagit, Vitner Einat B, Israeli Ofir, Milrot Elad, Stein Dana, Cohen-Gihon Inbar, Lazar Shlomi, Gutman Hila, Glinert Itai, Cherry Lilach, Vagima Yaron, Lazar Shirley, Weiss Shay, Ben-Shmuel Amir, Avraham Roy, Puni Reut, Lupu Edith, Bar-David Elad, Sittner Assa, Erez Noam, Zichel Ran, Mamroud Emanuelle, Mazor Ohad, Levy Haim, Laskar Orly, Yitzhaki Shmuel, Shapira Shmuel C, Zvi Anat, Beth-Din Adi, Paran Nir, Israely Tomer

Abstract excerpt

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Viral

Share to COVID-19 Vaccines

Share to Dose-Response Relationship, Immunologic

Share to Spike Glycoprotein, Coronavirus

Share to Vaccination

Share to Vaccines, Synthetic

Share to Vesicular stomatitis Indiana virus

Source

Open in PubMed Open full text

Identifiers

PMID: 33328475
DOI: 10.1038/s41467-020-20228-7
PMCID: PMC7745033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.PMID 33328475Read ↗

Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical diseaseSemantic proximity Read ↗

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.Semantic proximity Read ↗

A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2Semantic proximity Read ↗

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmissionSemantic proximity Read ↗

Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infectionSemantic proximity Read ↗

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.Semantic proximity Read ↗

Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell®Semantic proximity Read ↗

A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variantsSemantic proximity Read ↗

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosingSemantic proximity Read ↗

A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variantsSemantic proximity Read ↗

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamstersSemantic proximity Read ↗

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variantSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.